Enabling Access to Genomic Profiling Through the FDA- Authorized Decentralized Liquid Biopsy Solution, PGDx Elio™ Plasma Focus Dx

Liquid biopsy next-generation sequencing assays help guide treatment selection in cancer patients, particularly when tumor tissue is unavailable. Analytical validation an FDA authorized targeted 33-gene kitted assay, PGDx elio™ plasma focus Dx, has shown that detection of cancer-associated variants in ctDNA is highly specific, sensitive, reproducible and accurate.